MONTREAL, May 16 - Haemacure Corporation (TSX: HAE), a specialty bio-therapeutics company developing high-value human proteins for commercialization, announced today that its Chairman of the Board and Chief Executive Officer, Joseph Galli, will present at the upcoming Rodman & Renshaw 5th Annual Global Healthcare Conference on Tuesday, May 20, 2008 in the Zephyr Room at Le Méridien Beach Plaza Hotel in Monte Carlo, Monaco, beginning at 1:40 p.m Central European Summer Time (7:40 a.m. Eastern Daylight Time).

Rodman & Renshaw will webcast the audio portion of the presentation and post the associated slides via its website at www.rodmanandrenshaw.com, hosted by Wall Street Webcasting. To access the live broadcast via internet in listen-only mode, or the subsequently archived recording, simply cut and paste the following link directly into your web browser: http://www.wsw.com/webcast/rrshq13/h...

Please visit the site at least five minutes prior to start time for instructions.

About Rodman & Renshaw's Annual Global Healthcare Conference

The conference will include presentations by over 200 companies, as well as experts from the medical, scientific and investment communities. Details regarding the conference can be obtained at www.rodmanandrenshaw.com

Haemacure also announced today the resignation of Mr. Neil Weiner from the Board of Directors of the Company. "On behalf of the Board and management team, I wish to thank Neil for his tremendous contribution and dedication to Haemacure" commented Joseph Galli, Chairman and CEO of Haemacure.

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical hemostats. Haemacure's lead product candidate, Hemaseel(R)HMN, is a fibrin sealant planned to enter pivotal Phase II/Phase III clinical trials during the first quarter of 2009. Haemacure's second product candidate is thrombin, a component of its fibrin sealant, now in preclinical stage. Follow-on development will focus on surgical hemostats, wound healing, adhesion prevention, regenerative medecine, drug delivery and combination with biomaterials. Haemacure has discovered eleven additional specialty proteins and enzymes in one if its two plasma fractions and seeks to advance these proteins and enzymes through partnerships with pharmaceutical and biotechnology companies. Haemacure operates offices in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol HAE on the TSX.

Contacts

Haemacure Corporation: Joseph Galli
Chairman and CEO
(514) 990-7074
jgalli@haemacure.ca

Diane Roch
Director
Communications
(514) 282-3350 ext. 27
Cell.: (514) 952-3350
droch@haemacure.ca

www.haemacure.com